OKUR
OnKure Therapeutics, Inc. Class A Common StockOKUR
OKUR
About: OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
–
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$33
318%
upside
Avg. target
$36
356%
upside
High target
$40
407%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Leerink Partners Andrew Berens 40% 1-year accuracy 2 / 5 met price target | 318%upside $33 | Outperform Initiated | 5 Dec 2024 |
HC Wainwright & Co. Robert Burns 24% 1-year accuracy 37 / 155 met price target | 407%upside $40 | Buy Reiterated | 8 Nov 2024 |
Oppenheimer Matt Biegler 0% 1-year accuracy 0 / 1 met price target | 344%upside $35 | Outperform Initiated | 10 Oct 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219
-- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported
Neutral
GlobeNewsWire
4 weeks ago
OnKure Announces New Date for Upcoming Investor Call
Investor call to review preliminary data from the PIKture-01 trial is now planned for Tuesday, December 10th, at 7 a.m. CT Investor call to review preliminary data from the PIKture-01 trial is now planned for Tuesday, December 10th, at 7 a.m. CT
Neutral
GlobeNewsWire
1 month ago
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium
OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET
Positive
Seeking Alpha
2 months ago
OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond
Initial OnKure Therapeutics, Inc. data from the phase 1 PIKture-01 study, using OKI-219 for the treatment of patients with PI3Ka-H1047R breast cancer and solid tumors, is expected in Q4 of 2024. OKI-219 has 80X fold improved selectivity PI3K-a targeting versus wild-type PI3K-a, potentially allowing for higher dosing and reducing unwanted off-target effects. The merger with Reneo Pharmaceuticals and $65 million private placement boosts OnKure's cash to $139 million, funding operations into Q4 2026.
Charts implemented using Lightweight Charts™